Oregon legislators study ibogaine for treating PTSD and anxiety disorders

House Bill 3817, introduced in the Oregon State Legislature on April 16, 2025, aims to explore the therapeutic potential of ibogaine, a naturally occurring substance derived from the Tabernanthe iboga shrub. The bill directs the Oregon Health Authority (OHA) and the Department of Veterans’ Affairs (DVA) to study the use of ibogaine for treating specific mental health disorders, including post-traumatic stress disorder (PTSD), major depressive disorder, anxiety disorders, and substance use disorders.

Key provisions of the bill include the establishment of a process for individuals with these disorders to consume ibogaine under controlled conditions. The OHA and DVA are tasked with compiling a comprehensive report by September 15, 2029, which will assess the safety and efficacy of ibogaine, outline recommended dosages and delivery methods, and propose best practices for administration and client safety. Notably, the bill exempts ibogaine from the definition of a controlled substance when used within the established framework.

The introduction of House Bill 3817 has sparked discussions among lawmakers and health professionals regarding the potential benefits and risks associated with ibogaine treatment. Proponents argue that this bill could provide new avenues for individuals struggling with severe mental health issues, particularly veterans who may benefit from alternative therapies. However, concerns have been raised about the lack of extensive research on ibogaine's long-term effects and the need for rigorous safety protocols.

The bill is set to sunset on January 2, 2030, which means that its findings and recommendations could significantly influence future legislation regarding the use of ibogaine in Oregon. As the state grapples with rising mental health challenges, the outcomes of this study may have broader implications for treatment options available to residents.

In conclusion, House Bill 3817 represents a significant step towards investigating alternative therapies for mental health disorders in Oregon. The ongoing debates surrounding its provisions highlight the complexities of integrating new treatments into established healthcare frameworks, as stakeholders await the findings that could shape the future of mental health care in the state.